[Bolus of cyclophosphamide and methylprednisolone in uveitis in Behçet's disease. Preliminary results with the use of new criteria of evaluation].
In a prospective open trial, the effect of pulse cyclophosphamide or methylprednisolone in the treatment of Behçet's disease uveitis was studied. The therapeutic effect was evaluated based on two scores: one evolutive, reflecting ocular inflammation and calculated for each eye before and after therapy; and the other, a measure of disease severity, which took into consideration the irreversible damage. Patients who received cyclophosphamide pulse therapy (n = 8) had significantly lower evolutive scores (16.12 +/- 3.95, vs 10.37 +/- 8.53, p < 0.01) than the patients receiving classical methylprednisolone pulse therapy (n = 20), who had no significant changes in their evolutive scores (12.95 +/- 8.55, vs 10.05 +/- 8.56, p > 0.05).
Hamza
M
M
Service de Rhumatologie, Hôpital La Rabta, Tunis, Tunisie.
Meddeb
S
S
Mili
I
I
Ouertani
A
A
D000328:Adult; D001528:Behcet Syndrome / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D012720:Severity of Illness Index; D013997:Time Factors; D014605:Uveitis / Q000188:drug therapy*
D003520:Cyclophosphamide; D008775:Methylprednisolone
Les bolus de cyclophosphamide et de méthylprednisolone dans l'uvéite de la maladie de Behçet. Résultats préliminaires comportant l'utilisation de nouveaux critères d'évaluation.